

Supplementary Material

Table S1. Search Strategy

#1 (stroke OR ischaemic stroke OR haemorrhagic stroke OR transient ischaemic stroke OR poststroke OR cerebrovascular disorders OR basal ganglia cerebrovascular disease OR brain ischemia OR carotid artery diseases OR cerebral small vessel diseases OR intracranial arterial diseases or brain infarction OR subarachnoid haemorrhage).ab

AND

#2 (mHealth OR SMS text OR mobile applications OR cell phone OR social media OR smartphone OR apps OR automated phone calls OR telemedicine OR remote consultations OR medical technology).ab

AND

#3 medication adherence OR medication compliance OR patients adherence OR patients compliance OR persistence OR medic*

AND

#4 control trial OR randomized controlled trial or random*

Table S2. Baseline characteristics of included studies

Author, Setting	Population characteristics (n, Average Age, % of Male, Eligibility criteria)	Duration of Study	Delivery Mode	Outcome Measures
<i>Adie et al., 2010</i> UK	N = 56, 72.5 y, 46% male Diagnosis of minor stroke or TIA within one month, clinic SBP \geq 140 mmHg	6 months	Telephone	Behavioural: Medication adherence Clinical: sBP, dBP, LDL-C
<i>Hedegaard et al., 2014</i> Denmark	N = 211, 67 y, 61% male Diagnosis with acute first-time ischaemic stroke or TIA within the previous 30 days	12 months	Telephone	Behavioural: Medication adherence
<i>Kamal et al., 2015</i> Pakistan	N = 200, 56.8 y, 67.5% male Diagnosis of stroke, use at least two drugs to control risk factors of stroke	2 months	Automated SMS text messages	Behavioural: Medication adherence Clinical: dBP

<i>Kamal et al., 2018</i>	N = 201, 58.4 y, 77.2% male	3 months	Videos, mobile	Behavioural:
Pakistan	Diagnosis of cardiovascular disease or cerebrovascular accident		application	Medication adherence
<i>Kamal et al., 2020</i>	N = 310, 60.2 y, 67.4% male	12 months	Telephone and SMS	Clinical: dBp,
Pakistan	Diagnosis of first-time acute stroke with designated caregiver		text messages	sBP, LDL-C
<i>Labovitz et al., 2017</i>	N = 28, 57 y, 46.4% male	12 weeks	Mobile application	Behavioural:
USA	Diagnosis of ischaemic stroke, receiving anticoagulation drugs			Medication adherence
<i>Lakshminarayan et al., 2018</i>	N = 56, 65.6 y, 72% male	90 days	Telephone and email	Behavioural:
USA	Diagnosis of acute ischaemic stroke or intra-parenchymal haemorrhage			Medication adherence
				Clinical: sBP
<i>Ogren et al., 2018</i>	N = 871, 69.6 y, 59.2% male	36 months	Telephone	Clinical: sBP,
Sweden	Diagnosis of ischaemic stroke, TIA or intracerebral hematoma			dBp, LDL-C

<i>Wan et al., 2016</i>	N = 91, 59.7 y, 71.3% male	6 months	Telephone	Behavioural:
China	Diagnosis of ischaemic stroke			Medication adherence
<i>Yan et al., 2021</i>	N = 1299, 65.7 y, 57.4%	12 months	Voice message and	Behavioural:
China	Diagnosis of stroke		automated SMS text messages	Medication adherence Clinical: sBP, dBP

Abbreviations: Systolic blood pressure (sBP), Diastolic blood pressure (dBP), Transient ischaemic stroke (TIA), Low-density lipoprotein (LDL-C)

Table S3. Behavioural analysis of the intervention components

Study	Intervention group	Comparator group
<i>Adie et al., 2010</i>	<p>Description: Participants received telephone-based counselling that targeted their specific goals regarding lifestyle changes. These discussions reviewed BP, cholesterol control, medication, smoking, diet and physical activity. Educational materials tailored to the patients' needs were also provided.</p> <p>Delivery mode: Telephone Length and frequency: 20-minute call at 7-10 days, 1, 2 and 4 months Tailored advice: Yes COM-B: <i>Motivation</i> – setting goals and outcome expectations; <i>Opportunity</i> – provided social support</p>	<p>Description: Usual care with GP</p> <p>Delivery mode: Face-to-face Length and frequency: 6 months</p>
<i>Hedegaard et al., 2014</i>	<p>Description: Participants received focused medication review and an interview, then were followed up with telephone calls after discharge</p> <p>Delivery mode: Telephone Length and frequency: Contacted 1 week, 2 and 6 months after discharge Tailored advice: Yes COM-B: <i>Motivation</i> – Telephone follow-up on patients' plans that were set during motivational interviews, addressed any new medication problems, checked their medication adherence and summarised their progress according to their agreed plans; <i>Opportunity</i> – provided social support</p>	<p>Description: Standard care with short counselling about patients' lifestyles</p> <p>Delivery mode: Face-to-face Length and frequency: 12 months</p>
<i>Kamal et al., 2015</i>	<p>Description: Participants received automated SMS text message reminders according to their</p>	<p>Description: Usual care provided at the centre for stroke patients, including regular</p>

	<p>prescriptions. The participants were then required to reply to the text message regarding if they had taken their medication or not. SMS messages containing health information were also sent weekly to the participants, which were tailored according to the patients' drug and medical profiles.</p> <p>Delivery mode: SMS text messages Length and frequency: Reminder texts according to individuals' prescriptions and health information SMS sent weekly for 12 months Tailored advice: Yes COM-B: <i>Capability</i> – Reminders to improve cognitive functions</p>	<p>follow-up visits with stroke neurologists. Patients were provided with the telephone number of the stroke team in case of emergency, and they also received SMS messages or phone calls reminding them of their clinic appointments 1-2 days before</p> <p>Delivery mode: Face-to-face, SMS/phone call Length and frequency: 12 months</p>
<i>Kamal et al., 2018</i>	<p>Description: Participants received daily interactive voice response call services, tailored medication reminders, and lifestyle modification messages per week</p> <p>Delivery mode: Telephone and SMS text message Length and frequency: Daily calls, and weekly SMS messages for 3 months Tailored advice: Yes COM-B: <i>Capability</i> – improving patients' comprehension of lifestyle changes to prevent recurrent stroke, and improving cognitive functions by reminding medication adherence through SMS text messages</p>	<p>Description: Usual care and regular follow-up with stroke neurologist or cardiologist, also provided helpline number in case of emergency or queries about illness or medications</p> <p>Delivery mode: Face-to-face Length and frequency: 3 months</p>
<i>Kamal et al., 2020</i>	<p>Description: Participants were sent reminder messages to watch movies at home. Videos were shown to patients at time of discharge on</p>	<p>Description: Usual care, patients given information booklets and verbal instructions before discharge. Follow-up</p>

	<p>emergency preparedness, followed by second and third videos delivered after discharge covering frequently used medications, and strategies to prevent recurrent stroke</p> <p>Delivery mode: SMS text message, mobile application</p> <p>Length and frequency: Reminder messages sent twice a week, and videos delivered first and third month of follow-up after discharge</p> <p>Tailored advice: No</p> <p>COM-B: <i>Capability</i> – improve patients’ comprehension of disease and prescribed treatment, and improving patients’ cognitive functions by sending reminder text messages</p>	<p>appointments were provided after discharge</p> <p>Delivery mode: Face-to-face</p> <p>Length and frequency: 12 months</p>
<i>Labovitz et al., 2017</i>	<p>Description: AI platform AiCure monitored participants’ ingestions of prescribed anticoagulants. Any incorrect or missed doses were flagged on the AI platform, and the patient would be contacted by a study coordinator or the AiCure team</p> <p>Delivery mode: Mobile application</p> <p>Length and frequency: 12 weeks</p> <p>Tailored advice: No</p> <p>COM-B: <i>Capability</i> – reminder to improve cognitive functions</p>	<p>Description: Usual care</p> <p>Delivery mode: Face-to-face</p> <p>Length and frequency: 12 weeks</p>
<i>Lakshminarayanan et al., 2018</i>	<p>Description: Participants were provided with a wireless BP monitor and a smartphone to measure their daily BP. The data was automatically transmitted to a database monitored by</p>	<p>Description: Participants given BP monitor that did not transmit data automatically, and only shared BP data during clinic visits</p>

	<p>investigators, who then adjusted patients' medication prescription. Investigators communicated with patients via telephone and email to adjust medication prescription and provided advice on lifestyle modifications to improve adherence.</p> <p>Delivery mode: telephone, email Length and frequency: BP measured prior to breakfast, coffee or medication every day, participants' BP monitored biweekly for 90 days Tailored advice: Yes COM-B: <i>Opportunity</i> – provided social support; <i>Capability</i> – reminder to improve cognitive functions</p>	<p>Delivery mode: Face-to-face Length and frequency: 90 days</p>
Ogren et al., 2018	<p>Description: Participants received counselling and pharmacological treatment assessments via telephone. Medical treatments were adjusted by physicians if LDL-C and/or BP targets were not reached</p> <p>Delivery mode: Telephone Length and frequency: Physician consulting every 4 weeks when necessary for 36 months Tailored advice: Yes COM-B: <i>Motivation</i> – ensured that patients had correct perceptions of the illness and corrected their beliefs about treatment, encouraging outcome expectancies; <i>Opportunity</i> – provided social support</p>	<p>Description: In-hospital treatment and secondary preventative care after discharge based on local standards</p> <p>Delivery mode: Face-to-face Length and frequency: 36 months</p>
Wan et al., 2016	<p>Description: Participants received telephone follow-up conducted by stroke nurses. The calls</p>	<p>Description: Usual care that included educational brochures on stroke and its</p>

	<p>were structured, guideline-based and included goal-setting advice</p> <p>Delivery mode: Telephone</p> <p>Length and frequency: 15 to 20-minute telephone calls at 1 weeks, 1 and 3 months after discharge</p> <p>Tailored advice: Yes</p> <p>COM-B: <i>Motivation</i> – by setting goals and outcome expectations related to lifestyle changes according to each patients’ pre-stroke lifestyles; <i>Opportunity</i> – provided social support</p>	<p>risks. Routine measurements of BP and medication adherence after discharge</p> <p>Delivery mode: Face-to-face</p> <p>Length and frequency: 6 months</p>
<i>Yan et al., 2021</i>	<p>Description: Participants received daily voice messages or text messages that reminded them medication adherence and physical adherence along with tips</p> <p>Delivery mode: SMS text messages, voice messages</p> <p>Length and frequency: Daily messages for 12 months</p> <p>Tailored advice: No</p> <p>COM-B: <i>Capability</i> – reminder to improve cognitive functions</p>	<p>Description: Usual care</p> <p>Delivery mode: Face-to-face</p> <p>Length and frequency: 12 months</p>

Table S4. Included outcomes of eligible studies in the meta-analysis.

Continuous outcomes								
Study	Outcome	Measure	Mean		SD		Number of participants (n)	
			Intervention	Comparator	Intervention	Comparator	Intervention	Comparator
Adie et al., 2010	Medication adherence	Medication knowledge (%)	34	-9	60.1	48	29	27
	Systolic BP	mm Hg	-2.6	-4.6	20.3	19	29	27
	Diastolic BP	mm Hg	-10	-8.4	13	13.2	29	27
	Cholesterol	mmol/L	-0.9	-1	1.2	1	29	27
Hedegaard et al., 2014	Medication adherence	Composite medication possession ratio	0.06	0.12	0.7	0.9	100	100
Kamal et al., 2015	Medication adherence	MMAS scores	0.8	0.1	0.16	0.88	83	79
Kamal et al., 2018	Medication adherence	MMAS scores	0.66	0.4	1.15	1.32	50	47
Labovitz et al., 2017	Medication adherence	Cumulative adherence based on pill count	97.2	90.6	4.4	5.8	15	12
Lakshminarayan et al., 2018	Systolic BP	mm Hg	-9.8	-5.9	14.47	16.68	28	22
	Medication adherence	Mean knowledge scores	2.3	2.6	0.8	0.8	27	19
Ogren et al., 2018	Systolic BP	mm Hg	-8.8	-3	17.6	19.2	320	340

	Diastolic BP	mm Hg	-5.5	-1.4	13.2	12.7	320	340
	LDL-C	mmol/L	-0.3	0.1	1.1	1.1	320	340
Wan et al., 2016	Medication adherence	HPLP II scores	0.67	0.17	0.77	0.73	40	40
Yan et al., 2021	Systolic BP	mm Hg	-7.1	-4.3	18.5	18.9	611	615
	Diastolic BP	mm Hg	-3.9	-2.3	9.6	9.6	611	615
Dichotomous outcomes								
Events					Total			
Study	Outcome	Measure	Intervention	Comparator	Intervention	Comparator		
Hedegaard et al., 2014	Medication adherence	No. of adherent patients in year of follow-up	74	80	102	101		
Kamal et al., 2020	Systolic BP (goal)	No. of patients	18	11	54	52		
	Diastolic BP (goal)	No. of patients	44	37	54	52		
	LDL-C (goal)	No. of patients	36	30	51	51		
Labovitz et al., 2017	Medication adherence	No. of patients above goal drug concentration level	10	3	10	9		
Lakshminarayanan et al., 2018	Systolic BP (goal)	No. of patients	23	14	28	22		

Ogren et al., 2018	Systolic BP (goal)	No. of patients	254	188	320	340
	Diastolic BP (goal)	No. of patients	289	265	320	340
	LDL-C (goal)	No. of patients	222	166	320	340
Yan et al., 2021	Medication adherence	MGLS score	824	671	1134	1018

Table S5. Coding of intervention acceptability

Study	Measurement	Results
<i>Lakshminarayan et al., 2018</i>	Estimated acceptability by measuring elements of intervention usability of the interventions using the Marshfield Usability Survey (65) that is based on the Likert scale (1 = Strongly disagree, 5 = Strongly agree). They also asked patients about technical difficulties they faced while using the intervention as well as for unstructured feedback and suggestions for changes at the end of the trial.	High patient satisfaction with the interventions was found as most participants found it easy to use and convenient and thus, did not require additional help to use the system. They also reported that overall unstructured feedback was positive as participants liked the “instantaneous automatic transmission” of data directly to their healthcare providers. Some negative comments stated issues with technology such as phone running out of battery or confusion with the applications. Recommendations from patients included need for more training and clearer instructions for using the intervention.
<i>Labovitz et al., 2017</i>	Asked patients in the intervention group to complete a four-question satisfaction and usability questionnaires pre- and post-study.	Reported a 10% increase from 73.3% to 83.3% of patient satisfaction.
<i>Kamal et al., 2015</i>	Asked patients to complete two questionnaires, including a self-reported questionnaire and another that reported satisfaction based on previous literature (66).	Recorded 96.07% patient satisfaction and 95.6% acceptability of the mHealth intervention.
<i>Kamal et al., 2018</i>	Conducted open-ended interviews asking participants about their opinions and recommendations on	Found that majority of patients were satisfied with the intervention as they found it “excellent”, “useful”, “convenient” and “informative”.

	how to further improve the interventions.	Patients suggested to reduce total duration of calls, simplify information provided to them, add pictorial messages and to add local languages to increase accessibility of the intervention in local communities.
<i>Hedegaard et al., 2014</i>	Asked patients to rate their satisfaction with specific intervention elements, including their views on the received medication adherence care.	Majority of patients were “very satisfied” with the intervention.




Figure S1. Subgroup analysis, intervention content, continuous outcome




Figure S2. Subgroup analysis, intervention content, dichotomous outcome




Figure S3. Subgroup analysis, outcome measurement, continuous outcome




Figure S4. Subgroup analysis, outcome measurement, dichotomous outcome




Figure S5. Funnel plot for adherence continuous outcomes




Figure S6. Funnel plot for adherence dichotomous outcomes




Figure S7. Funnel plot for sBP continuous outcomes




Figure S8. Funnel plot for sBP dichotomous outcomes




Figure S9. Funnel plot for dBP continuous outcomes




Figure S10. Funnel plot for dBP dichotomous outcomes




Figure S11. Funnel plot for LDL-C continuous outcomes




Figure S12. Funnel plot for LDL-C dichotomous outcomes